How do strategic investors identify promising science and help turn it into a company?
Christian Schubert, Vice President and Global Head of AbbVie Ventures, joins David Berry on Averin Insights to discuss early-stage biotech investing, working with founders, and where AI can make a meaningful difference in drug discovery.
The conversation explores how corporate venture capital is evolving, how investors build conviction in emerging biology, and what it takes to move scientific ideas toward new medicines.
